GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mira Pharmaceuticals Inc (STU:K6S) » Definitions » Notes Receivable

Mira Pharmaceuticals (STU:K6S) Notes Receivable : €0.00 Mil (As of Mar. 2025)


View and export this data going back to 2024. Start your Free Trial

What is Mira Pharmaceuticals Notes Receivable?

Mira Pharmaceuticals's Notes Receivable for the quarter that ended in Mar. 2025 was €0.00 Mil.


Mira Pharmaceuticals Notes Receivable Historical Data

The historical data trend for Mira Pharmaceuticals's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mira Pharmaceuticals Notes Receivable Chart

Mira Pharmaceuticals Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Notes Receivable
- - - -

Mira Pharmaceuticals Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Mira Pharmaceuticals Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Mira Pharmaceuticals Notes Receivable Related Terms

Thank you for viewing the detailed overview of Mira Pharmaceuticals's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Mira Pharmaceuticals Business Description

Traded in Other Exchanges
Address
1200 Brickell Avenue, Suite 1950 No. 1183, Miami, FL, USA, 33133
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.

Mira Pharmaceuticals Headlines

No Headlines